February 5, 2008Annals of Internal Medicine
Balancing Efficacy and Safety of Drug-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
Key result
DES provide net clinical benefit over BMS despite late thrombosis risk, requiring uninterrupted antiplatelet therapy.
Why the study?
The safety and net clinical effects of drug-eluting stents compared with bare-metal stents remain uncertain due to contradictory results and concerns about late stent thrombosis.
Do drug-eluting stents provide a net clinical benefit compared with bare-metal stents in patients undergoing percutaneous coronary intervention?
Population
Patients undergoing percutaneous coronary intervention
Comparison
Drug-eluting stents vs bare-metal stents
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Favors DES over BMS for STEMI PCI; confirms reduced restenosis without excess late thrombosis.
Structured PICO
Do drug-eluting stents provide a net clinical benefit compared with bare-metal stents in patients undergoing percutaneous coronary intervention?
P
Population
Patients undergoing percutaneous coronary intervention
I
Intervention
Drug-eluting stents
C
Comparator
Bare-metal stents
O
Outcome
Net clinical effects (efficacy including in-stent restenosis and target vessel revascularization vs. safety including late stent thrombosis)
Drug-eluting stents offer a net clinical benefit over bare-metal stents by reducing restenosis, though they require careful patient selection to ensure adherence to prolonged antiplatelet therapy to mitigate the risk of late stent thrombosis.
Limitations
- Larger, adequately powered, randomized trials are needed to fully assess the net clinical effects of drug-eluting stents compared with bare-metal stents.
- Existing research often reaches contradictory results even with analyses of the same data.
- Contradictory results in existing research
- Need for larger, adequately powered randomized trials
Cite This Study
Jeremias et al. (2008) conducted a review in Obstructive coronary artery disease requiring percutaneous coronary intervention. Drug-eluting stents vs. Bare-metal stents was evaluated. Drug-eluting stents provide a net clinical benefit that outweighs the risks of late stent thrombosis compared with bare-metal stents, provided uninterrupted antiplatelet therapy is maintained.